Effect of the selective dopamine D sub(3) receptor antagonist SB-277011-A on regional c-Fos-like expression in rat forebrain

SB-277011-A is a dopamine D sub(3) receptor antagonist that exhibits over 100-fold selectivity over dopamine D sub(2) receptors and a broad spectrum of other receptor, ion channels, and enzymes. We employed c-Fos immunohistochemistry to characterise the functional neuroanatomical effects of acute ad...

Full description

Saved in:
Bibliographic Details
Published in:Brain research Vol. 1149; pp. 50 - 57
Main Authors: Southam, E, Lloyd, A, Jennings, CA, Cluderay, JE, Cilia, J, Gartlon, JE, Jones, DNC
Format: Journal Article
Language:English
Published: 14-05-2007
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SB-277011-A is a dopamine D sub(3) receptor antagonist that exhibits over 100-fold selectivity over dopamine D sub(2) receptors and a broad spectrum of other receptor, ion channels, and enzymes. We employed c-Fos immunohistochemistry to characterise the functional neuroanatomical effects of acute administration of SB-277011-A and observed a time-dependent increase in the density of c-Fos-like positive nuclei in rat forebrain with maximal effects observed 2 h post-dose. The relative influence of the different brain regions on the overall effect of SB-277011-A was ranked by partial least squares discriminant analysis loadings plot which indicated that sites within the nucleus accumbens exerted the greatest influence on the separation of the vehicle and SB-277011-A treatment groups. At the 2 h time-point, c-Fos-like expression was shown to be significantly elevated (p<0.05) in the core and shell of the nucleus accumbens, at both rostral and caudal levels, and in the lateral septum. No significant changes were detected in the caudate nucleus (lateral or medial) or in the cingulate, infralimbic prefrontal, or somatosensory cortices. The capacity of SB-277011-A to trigger immediate early gene expression in these limbic regions of rat brain adds to a growing consensus of the potential utility of dopamine D sub(3) receptor antagonism in psychiatric disorders including schizophrenia and drug dependency.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-2
ISSN:0006-8993
DOI:10.1016/j.brainres.2007.02.051